See Who Selected our Software for Pharmaceutical Companies

Achieve Life Sciences
Achieve Life Sciences is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.

Adagio Therapeutics
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses.

Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals is developing superior neuroprotective medicines for the treatment of central nervous system disorders.

Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on a breakthrough discovery that enables the creation of a broad new class of human therapeutics.

Athersys, Inc.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas.

Atreca
Developing novel therapeutics based on a deep understanding of the human immune response.

Beam Therapeutics
Beam is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases.

Catalyst Biosciences
Catalyst Biosciences is a leading biotechnology company focused on developing proteases as a therapeutic platform for inflammation, cardiovascular, and angiogenesis-based disorders.

Celsius Therapeutics
Celsius is leveraging the power of personalized medicine to develop treatments for complex diseases such as autoimmunity and cancer.

Cytokinetics Inc.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Enanta Pharmaceuticals
Enanta is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering and developing novel inhibitors designed for use against the hepatitis C virus, or HCV.

Exelixis
Exelixis is on a mission to help cancer patients recover stronger and live longer.

FivePríme Therapeutics, Inc.
FivePrime Therapeutics is developing treatments for cancer and diabetes and multiple leads in metabolic and immunologic diseases, oncology and regenerative medicine.

Flagship Pioneering
Flagship conceives, creates, resources and grows first-in-category life sciences companies.

FORMA Therapeutics
At FORMA Therapeutics, we are passionate about discovering and developing medicines that will make a difference in cancer and other genetically-driven diseases. Our drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions.

Intellia
Intellia is a leading gene editing company focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system.

Ipsen
Ipsen US, comprised of Ipsen Biopharmaceuticals, Inc., and Ipsen Bioscience, Inc., is driven by a passion to improve the lives of patients. A search for innovative solutions to disabling conditions is at the heart of everything we do. We are inspired to find effective therapeutic options to treat diseases, relieve suffering, and bring value to the community.

Karyopharm Therapeutics, Inc.
is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

MacroGenics, Inc.
MacroGenics is focused on applying its world-class antibody capabilities to discover, develop and deliver to patients novel biologics for the treatment of autoimmune disorders, cancer and infectious diseases.

Molecular Templates
Engineering a new protein scaffold with unique biology to create novel drugs for cancer.

Nurix, Inc.
Nurix is a leader in discovering and developing a new class of drugs that work by modulating the protein regulation machinery of the cell. The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS).

PNIDigitalMedia
PNI provides a proprietary transactional software platform that is used by leading retailers such as Costco, Walmart Canada, and CVS/pharmacy to sell millions of personalized products every year.

Retrophin
is a biopharmaceutical company focused on the discovery and development of drugs for the treatment of catastrophic diseases that are debilitating and often life-threatening, and for which there are currently limited patient options.

Spero Therapeutics
Spero Therapeutics' vision extends beyond the current horizon of anti-infectives to find, develop, and advance groundbreaking therapeutics that meet critical patient needs in infectious disease.

Sutro
Sutro is developing a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies.

Turning Point Therapeutics
A Turning point for precision oncology. Targeted cancer therapies designed to address treatment resistance and improve lives.

Turnstone Biologics
Turnstone Biologics is transforming patient care with a new class of targeted viral immunotherapies to fight cancer.

Viking Therapeutics
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking's R&D activities leverage the company's expertise in metabolism to develop innovative therapeutics that improve patients' lives.

XOMA Corporation
XOMA has built a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research.